Tumor‐Specific On‐Site Activation of Cisplatin via Cascade Catalytic‐Redox Reactions for Highly Efficient Chemo‐Immunotherapy
Angewandte Chemie International Edition · 07.07.2025 · 64 (28)
DOI: 10.1002/anie.202500996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 15.05.2025. Verfasst von Gang-Gang Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering Anhui University of Technology, Ma'anshan, Anhui, 243002, P.R. China. Hauptthemen laut MEDLINE: Cisplatin, Antineoplastic Agents, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.
Abstract (Originalsprache)
The therapeutic efficiency of platinum drugs is always limited by low utilization, side effects, and Pt‐resistance. Herein, a double‐lock protected Pt II nanomedicine named PtNP@Cu has been developed, which performs cascade unlocking of dechlorinated cisplatin ( DP ) via catalytic‐redox reactions, thus achieving tumor‐specific “on‐site” activation of cisplatin ( cDDP ) in the nucleus accompanied with substantial induction of ferroptosis of cancer cells. This design avoids the premature release of active Pt II species in normal cells or in the cytoplasm of cancer cells before reaching nucleus, thereby ensuring maximum amplification of Pt‐DNA crosslinking with tumor‐specificity. Meanwhile, substantial GSH depletion and ROS production induced by cascade catalytic‐redox reactions results in ferroptosis of cancer cells, which further reduces GSH‐mediated cDDP detoxification, overcomes Pt‐resistance, and enhances immunogenicity, ultimately realizing highly efficient tumor‐specific chemotherapy and antitumor immunity in vivo. This work provides a new strategy for effectively and comprehensively addressing the issues of low utilization, side effects, and drug resistance problems of platinum drugs, which is also promising for chemo‐immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering Anhui University of Technology, Ma'anshan, Anhui, 243002, P.R. China.
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, GBRCE for Functional Molecular Engineering, School of Chemistry, Sun Yat-Sen University, Guangzhou, 510006, P.R. China.
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Guangdong Basic and Applied Basic Research Foundation
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Yang, G. G., Liu, B., Liu, W., Zhang, L., Ke, C., Han, X., Cao, Q., & Mao, Z. W. (2025). Tumor‐Specific On‐Site Activation of Cisplatin via Cascade Catalytic‐Redox Reactions for Highly Efficient Chemo‐Immunotherapy. Angewandte Chemie International Edition, 64(28). https://doi.org/10.1002/anie.202500996
Vancouver
Yang GG, Liu B, Liu W, Zhang L, Ke C, Han X, et al. Tumor‐Specific On‐Site Activation of Cisplatin via Cascade Catalytic‐Redox Reactions for Highly Efficient Chemo‐Immunotherapy. Angewandte Chemie International Edition. 2025;64(28). doi:10.1002/anie.202500996
BibTeX
@article{Yang2025,
author = {Yang, Gang-Gang and Liu, Bin and Liu, Wei and Zhang, Lan and Ke, Can and Han, Xinya and Cao, Qian and Mao, Zong-Wan},
title = {Tumor‐Specific On‐Site Activation of Cisplatin via Cascade Catalytic‐Redox Reactions for Highly Efficient Chemo‐Immunotherapy},
journal = {Angewandte Chemie International Edition},
year = {2025},
volume = {64},
number = {28},
doi = {10.1002/anie.202500996}
}
EUVIMED